Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Employees: 352
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 28
63% more call options, than puts
Call options by funds: $54.3M | Put options by funds: $33.3M
40% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]
37% more capital invested
Capital invested by funds: $2.95B [Q2] → $4.04B (+$1.1B) [Q3]
11% more funds holding
Funds holding: 284 [Q2] → 315 (+31) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 104
3.53% less ownership
Funds ownership: 87.17% [Q2] → 83.64% (-3.53%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$80
33%
upside
Avg. target
$80
33%
upside
High target
$80
33%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 32% 1-year accuracy 61 / 188 met price target | 33%upside $80 | Buy Reiterated | 31 Oct 2024 |
Financial journalist opinion
Based on 8 articles about CORT published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Neutral
PRNewsWire
2 days ago
Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Zacks Investment Research
2 days ago
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Positive
Seeking Alpha
4 days ago
Corcept Therapeutics Generating Strong Revenue And Profit Growth
Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is poised to take the company to the next level. Long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant, which could expand market reach beyond Korlym.
Positive
Investors Business Daily
4 days ago
Medical Stock Soars To Highs As Cortisol Screening Grows
Corcept Therapeutics makes drugs that modulate cortisol. The post Medical Stock Soars To Highs As Cortisol Screening Grows appeared first on Investor's Business Daily.
Positive
Zacks Investment Research
3 weeks ago
Corcept Submits Application for Another Cushing's Syndrome Drug
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
Neutral
Business Wire
3 weeks ago
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolis.
Neutral
Business Wire
1 month ago
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogenous hypercortisolism (Cushing's syndrome) at the WCIRDC. The results from this.
Neutral
Business Wire
1 month ago
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism (Cushing's syn.
Positive
Zacks Investment Research
1 month ago
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
Charts implemented using Lightweight Charts™